Further, we developed original CRISPR/Cas9 cells for cN-II and/or CD73 obtaining breast and lung cancer cell models expressing none, both or one of the proteins, thus enabling the evaluation of concomitant roles of the two proteins in cancer cell biology [20,21]. The gene discussed is NT5C2; the disease is lung carcinoma.